Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

0.2955 -0.0645 (-17.92%)
Delayed Quote Updated: 2:24 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key HighlightsTarget generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by... 
Via Newsfile
Topics Artificial Intelligence
News headline image
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions 
From KALA BIO, Inc.
Via GlobeNewswire
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program 
From KALA BIO, Inc.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
From KALA BIO, Inc.
Via GlobeNewswire
InvestorNewsBreaks – KALA BIO, Inc. (NASDAQ: KALA) Implements 1-For-50 Reverse Stock Split
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
KALA BIO Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on May 11, 2026 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI... 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
From KALA BIO, Inc.
Via GlobeNewswire
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
Which stocks have an unusual volume on Thursday? ↗
Via Chartmill
These stocks are making the most noise in today's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Younet.ai, a Toronto-based AI technology company specializing in enterprise-grade private LLM solutions,... 
Via Newsfile
Topics Artificial Intelligence
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Why Did KALA Stock Surge 70% In Pre-Market Today? ↗
The company said that it is ready to deploy its new AI platform, Researgency, within 14 days. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks 
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
$167 Billion Invested in Biotech R&D is Underserved by AI, Offering Huge Opportunity for New On-Premises AI Infrastructure Platform from KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform
From KALA BIO, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.